Locoregional therapies in the treatment of 3-to 5-cm hepatocellular carcinoma: Critical review of the literature

Shamar Young, Jafar Golzarian

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


OBJECTIVE. Treatment options for hepatocellular carcinoma (HCC) continue to expand. However, given the complexity of the patients including factors such as codominant cirrhosis or portal hypertension and transplant status, it can be difficult to know which treatment is most advantageous. The choice of HCC treatment is perhaps most complex in the setting of HCCs that are 3–5 cm. This article reviews the evidence for locoregional therapies in treating 3-to 5-cm HCCs. CONCLUSION. Combination therapy with transarterial chemoembolization (TACE) and ablation has the most robust and highest level of evidence to support its efficacy and therefore should be considered first-line therapy for nonresectable HCCs that measure 3–5 cm. The studies support that TACE followed by ablation is superior to either TACE alone or ablation alone. Data for transarterial radioembolization (TARE) to treat HCCs in this specific size range are very limited. Additional data are needed about the comparative effectiveness of TACE-ablation combination and TARE and how the TACE-ablation combination compares with surgical resection.

Original languageEnglish (US)
Pages (from-to)223-234
Number of pages12
JournalAmerican Journal of Roentgenology
Issue number1
StatePublished - Jul 2020

Bibliographical note

Publisher Copyright:
© American Roentgen Ray Society.


  • Chemoembolization
  • Hepatocellular carcinoma
  • Microwave ablation
  • Radiofrequency ablation
  • Transarterial radioembolization

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Locoregional therapies in the treatment of 3-to 5-cm hepatocellular carcinoma: Critical review of the literature'. Together they form a unique fingerprint.

Cite this